| SC 13D/A | 2022-07-11 | Innoviva, Inc. | Entasis Therapeutics Holdings Inc. | 100 | 100.0% | EDGAR |
| SC 13D/A | 2022-05-24 | Innoviva, Inc. | Entasis Therapeutics Holdings Inc. | 57,345,794 | 74.9% | EDGAR |
| SC 13D/A | 2022-03-15 | Innoviva, Inc. | Entasis Therapeutics Holdings Inc. | 57,345,794 | 74.9% | EDGAR |
| SC 13D/A | 2022-02-22 | Innoviva, Inc. | Entasis Therapeutics Holdings Inc. | 57,345,794 | 75.2% | EDGAR |
| SC 13G/A | 2022-02-14 | EVENTIDE ASSET MANAGEMENT, LLC | Entasis Therapeutics Holdings Inc. | 590,602 | 1.2% | EDGAR |
| SC 13D/A | 2022-02-02 | Innoviva, Inc. | Entasis Therapeutics Holdings Inc. | 57,345,794 | 75.2% | EDGAR |
| SC 13D/A | 2022-01-18 | TPG GP A, LLC | Entasis Therapeutics Holdings Inc. | 1,020,748 | 2.1% | EDGAR |
| SC 13D/A | 2021-06-14 | Innoviva, Inc. | Entasis Therapeutics Holdings Inc. | 57,345,794 | 75.5% | EDGAR |
| SC 13D/A | 2021-05-03 | Innoviva, Inc. | Entasis Therapeutics Holdings Inc. | 44,807,844 | 70.6% | EDGAR |
| SC 13D/A | 2021-03-04 | Sofinnova Venture Partners IX, L.P. | Entasis Therapeutics Holdings Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2021-02-16 | ARMISTICE CAPITAL, LLC | Entasis Therapeutics Holdings Inc. | 1,863,198 | 5.0% | EDGAR |
| SC 13G | 2020-09-08 | ARMISTICE CAPITAL, LLC | Entasis Therapeutics Holdings Inc. | 3,510,981 | 9.9% | EDGAR |
| SC 13D/A | 2020-09-01 | Innoviva, Inc. | Entasis Therapeutics Holdings Inc. | 37,345,794 | 69.0% | EDGAR |
| SC 13D/A | 2020-08-31 | Innoviva, Inc. | Entasis Therapeutics Holdings Inc. | 28,000,000 | 67.8% | EDGAR |
| SC 13G/A | 2020-08-11 | Novo Holdings A/S | Entasis Therapeutics Holdings Inc. | 1,173,896 | 4.3% | EDGAR |
| SC 13D/A | 2020-07-09 | Clarus Lifesciences III, L.P. | Entasis Therapeutics Holdings Inc. | 1,339,836 | 4.9% | EDGAR |
| SC 13D/A | 2020-06-18 | Frazier Life Sciences VIII, L.P. | Entasis Therapeutics Holdings Inc. | 799,953 | 2.9% | EDGAR |
| SC 13G/A | 2020-06-16 | Novo Holdings A/S | Entasis Therapeutics Holdings Inc. | 2,181,843 | 8.0% | EDGAR |
| SC 13D/A | 2020-06-12 | Innoviva, Inc. | Entasis Therapeutics Holdings Inc. | 28,000,000 | 67.8% | EDGAR |
| SC 13D/A | 2020-05-01 | Clarus Lifesciences III, L.P. | Entasis Therapeutics Holdings Inc. | 1,623,405 | 11.1% | EDGAR |